As of Jan 22
| +0.10 / +1.59%|
The 3 analysts offering 12-month price forecasts for Arrowhead Pharmaceuticals Inc have a median target of 3.00, with a high estimate of 5.50 and a low estimate of 2.00. The median estimate represents a -53.05% decrease from the last price of 6.39.
The current consensus among 4 polled investment analysts is to Buy stock in Arrowhead Pharmaceuticals Inc. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.